"Should also train teachers on how we can prevent COVID": Odisha Minister Nityananda Gond
Bhubaneswar (Odisha) [India], June 7 (ANI): Odisha Education Minister Nityananda Gond said the government is cautious about COVID-19 and that teachers should be trained to prevent COVID-19 infection when exposure to the virus cannot be avoided.
Speaking to ANI on Friday, Minister Nityananda Gond said, '...We are cautious in this regard, and we will follow the instructions issued by the Government of India and the state government... We should also train teachers on how we can prevent COVID infection at a time when we cannot avoid exposure...'
According to the Union Ministry of Health, there were 23 active COVID-19 cases in Odisha as of 8 AM on June 7. On Sunday, the number of active COVID-19 cases in the state was 12, according to the Director of Public Health, Government of Odisha, Dr Nilakantha Mishra.
'The number of cases is very low, and almost all patients diagnosed with COVID have mild symptoms. They are being treated in isolation in their own homes,' Dr Mishra told ANI.
He further reassured the public, stating that the variants detected in the state are sublineages of Omicron, and there is no cause for concern at this point. 'There is nothing to worry about in Odisha. The variants that have been detected are also Omicron variants,' he added.
As of June 7, 2025, at 8 AM, India reported 5364 active COVID-19 cases. Most cases are mild and managed under home care.
Since January 1, 2025, 55 deaths have been reported, primarily among individuals with pre-existing illnesses. States have been instructed to ensure the availability of oxygen, isolation beds, ventilators, and essential medicines.
In view of the recent increase in COVID-19 cases in India, a series of technical review meetings were held on June 2 and 3 with various representatives under the chairpersonship of Dr Sunita Sharma, Director General of Health Services (DGHS).
According to a press release, the representatives include Disaster Management Cell, Emergency Management Response (EMR) Cell, National Centre for Disease Control (NCDC), Indian Council of Medical Research (ICMR), Integrated Disease Surveillance Programme (IDSP) and Central Government Hospitals in Delhi and with representatives from all States and UTs to evaluate the current COVID-19 situation and preparedness measures. (ANI)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
37 minutes ago
- Time of India
One cough too many: India's TB fight isn't quite there yet
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads MISSING CASES Tired of too many ads? Remove Ads NEW HOPE, OLD GAPS A CURE WITH ISSUES WHAT NEXT? One moment Anushka (name changed) was a college student. Then her world turned upside down. It started with a persistent cough and high fever. Despite popping meds, it wouldn't go away. Tests followed and then came the news that knocked the stuffing out of her—she had a fatal form of tuberculosis TB ). With scarred lungs, she gasped for each breath. The bacteria had killed her appetite, making her frail and bony. Her skin colour changed—to dark and then grew paler. At 20, her life expectancy dwindled to a few months.'I felt weak,' she recalls, 'and preferred to be alone.'Battling extensively drug-resistant tuberculosis or XDR-TB, a form of the disease in which drugs rarely worked, Anushka's only option was to be loaded each day with scores of tablets and injections. Those came with toxic side effects. For over four years, she moved between government and private hospitals, enduring cycles of failed came only when she was placed on a salvage regimen—the last option when all other interventions are exhausted—at a Médecins Sans Frontières (MSF) clinic in Govandi, Mumbai. The global humanitarian group offered Anushka a cocktail of bedaquiline , delamanid and imipenem injections, a set of very powerful meds often inaccessible to most Indians due to supply restrictions aimed at curbing drug who has now recovered, recounted her ordeal at MSF's TB Day event in Mumbai on May 12, speaking before an audience of doctors, a quiet smile breaking through years of pain. Her journey to recovery is rare, and alien to millions in India, which reflects a public health system still failing its most vulnerable. India now accounts for more than a quarter of all TB cases reported worldwide. In 2023, the country had 26% of the global TB burden, according to the World Health Organization (WHO). Bending the curve remains difficult despite multiple national can India improve?In 2018, when India pledged to eliminate TB by 2025, five years ahead of the set global target, the objective was clear. And progress has been made, too. Between 2015 and 2023, TB incidence (new and relapsed cases per 1 lakh population every year) fell by 18% and deaths by 24%, per is a sign in the right direction, but the number of cases are still astounding, especially when it comes to drug-resistant variants. 'India bears the highest burden of XDR-TB globally, with an estimated 110,000 new cases annually,' says Professor Anil Koul of the London School of Hygiene and Tropical Medicine. A key figure in TB drug research, Koul was part of a Johnson & Johnson team that developed bedaquiline, one of the most effective drugs against resistant TB notes that Covid-19 deepened the crisis, and underfunded research has stalled progress. Of the 27 drugs in clinical trials, none have reached Phase III. Bedaquiline remains the mainstay.A 100-day TB Elimination Challenge was launched by the government in December 2024 to amplify efforts to diagnose and treat TB at the village level, but experts aren't satisfied.'We are not on track,' says Dr Animesh Sinha, chronic care and infectious disease advisor, MSF. 'To meet the 2025 milestones of WHO's End TB strategy, India should achieve a 50% reduction in TB incidence rate and a 75% reduction in the total number of TB deaths compared with 2015.' Although numbers have fallen, the quantum has been woefully short of the target, as WHO numbers suggest.A PIB release dated March 24, 2025, says India's TB elimination targets for 2025 are an 80% reduction in incidence and a 90% reduction in deaths, compared with 2015.A key problem is underreporting emanating from under-diagnosis. India's notification rate (number of TB cases diagnosed and officially reported) has improved from 108 per 100,000 population in 2010 to 166 in 2023, yet many cases, especially in rural areas, go undetected.'In order to address the TB crisis, we have to find the missing cases,' says Sinha. Nonetheless, the 2025 goal helped push TB up the political agenda. Ni-kshay, a digital platform for notification and treatment monitoring, is improving reporting. But without proportionate investment in diagnostics, staffing and drug access, the pace of progress will be drug shortages have been reported, and India spent just 2.1% of the National Tuberculosis Elimination Programme budget on diagnostics till 2023-24, an IndiaSpend RTI revealed.'The 2025 target was always a stretch,' says Koul. 'But it did galvanise government machinery, leading to faster approvals for newer regimens like bedaquiline, speedier rollout across TB centres and more budgetary support, including for nutritional aid.'That said, TB continues to receive only a sliver of public health funding. But even so, he notes, there certainly is a positive trend in fighting back, considering the complexity of the disease and the socioeconomic factors shaping in an ET Morning Brief podcast in January, Dr Urvashi Singh, deputy director-general (TB), Ministry of Health and Family Welfare, said, 'The domestic budget for the national TB programme has increased over five times in the last 10 years.' India, she added, is the only high-burden country where 91% of the programme is backed by domestic detection is often the difference between quick recovery and years of suffering. Goa-based diagnostic device maker Molbio Diagnostics' Truenat, a portable molecular-testing platform, introduced in 2017, expanded diagnostic access, particularly in low-access regions. 'We supplied over 90 lakh testing kits last year and expect to provide 1.25 crore this year,' says Sriram Natarajan, CEO of Molbio, which is working with government and statelevel partners to rollout molecular testing.A Truenat test costs just Rs 640, a fraction of what imported diagnostics demand, says Natarajan. In public health, he argues, the real measure isn't price, but cost-effectiveness, especially when early detection can avert far greater globally approved diagnostics protocols remain out of reach in India. The WHO-recommended urine TBLAM test, used to diagnose TB in HIVpositive patients, is still unavailable in the country, despite successful validation studies in Mumbai in 2022. Registration barriers and lack of supply from manufacturers have led to lack of access, says Leena Menghaney, a public health lawyer based in Delhi. Supplyrelated issues could be because trials in India have yet to conclude, according to industry delays cost precious lives. Late detection risks high transmission rates and complications for patients. Dr Jennifer Furin, infectious diseases clinician, Harvard Medical School, says while Truenat is helpful and the diagnostic pipeline is robust, the outdated and slow systems for approving novel tools in India have a detrimental impact. Furin points to a critical gap: the lack of household-level prevention. Studies, including a 2023 trial published in TheLancet, show that modest nutritional support for families of TB patients can sharply reduce transmission. Another model, published in TheLancet this year, estimates that improving household nutrition alone could prevent nearly 5% of TB deaths by carrying the world's highest TB burden, regulatory reforms have been slow in India. Some gains have been made, but systemic delays continue to blunt the impact of new patients with drug-resistant TB, a new wave of treatment offers hope, but conditions apply. Regimens like a six-month, all-oral combination termed BPaLM— bedaquiline, pretomanid, linezolid and moxifloxacin—have been game-changers, replacing the gruelling 24-month regimens of daily injections and pills. 'These regimens are better tolerated and highly effective, with about 90% of people completing treatment successfully,' says clinicians welcome the government's push for shorter regimens, access remains limited—only 1,700 patients in India have received them, according to Dr Rupak Singla, head of the department of respiratory medicine, National Institute of Tuberculosis and Respiratory Diseases , Delhi, who spoke at the event in Mumbai. Adoption has lagged due to limited access to drug susceptibility testing for newer drugs, which is crucial for choosing an appropriate treatment BPaLM regimen can't be given in cases where more than one organ system is involved or in patients with severe extrapulmonary disease, 'both of which are common in India,' according to Dr Alpa Dalal, head of unit, Group of TB Hospitals, Sewri, Mumbai. BPaLM should not be prescribed for patients previously treated with bedaquiline, says Dalal, unless drug susceptibility to bedaquiline and linezolid is says even in extensive pulmonary TB, where studies have shown good outcomes with BPaLM, many clinicians are cautious. In longer regimens, patients with extensive lung involvement have had higher relapse rates, compared with patients with limited disease, she explains, and that concern carries over. A study published in OUP's research platform, Oxford Academic, in March 2025 shows that bedaquiline resistance among previously treated patients can reduce the drug's warn that such resistance could undercut its effectiveness in the long term if not addressed early. But Koul says, 'Bedaquiline has galvanised TB R&D. It will remain a core component of future regimens, unless we see a dramatic rise in resistance in clinical practice.'The economics of care create barriers too. Pricing is a big hurdle. Regimens with imipenem cost thousands of rupees per day. Anushka was treated free by MSF. Else each injection alone, she said, would cost Rs 2,499. Considering the socioeconomic realities of India, perhaps this is where the government could step approach to procurement is problematic too. The country selectively joins pooled procurement platforms like the Global Drug Facility, which could reduce costs. 'India has in the past refused to participate in this, unless they had an emergency,' says policy and procurement, TB is a profoundly social disease, shaped by stigma, poverty and undernutrition. Even the best drugs won't work if care doesn't reach those who need it most. Guidelines may improve and approvals may accelerate but until the system meets people where they are, too many will be left suffered for years before she got cured. Her strength wasn't just in surviving; it was in refusing to give up. 'Even in that condition, I completed my graduation and kept chasing my dreams,' she says. India's TB response must now rise to match that grit, with urgency, equity and compassion.
Hindustan Times
40 minutes ago
- Hindustan Times
Ludhiana: 3 new cases take Covid tally to 21
Three new Covid-19 positive cases were reported in the district on Saturday, taking the tally to 21. While two of the new cases, a 38-year-old man and 23-year-old woman, are mildly symptomatic, a 53-year-old man has been hospitalised. According to a senior health official, the patient is only on L2 care which includes oxygen but doesn't include other invasive treatments like those needed in L3 care. The hospitalised man had taken three shots of the vaccine. The mildly symptomatic woman and man had taken three and two shots of vaccine, respectively. Of these 21 cases, only 16 are active. Three of the patients have recovered while two have died so far. Fifteen patients are in home isolation. Both the deaths, one on last Wednesday and the second this Wednesday, were cases of comorbid patients. While the first death was of a 40-year-old suffered from a lung ailment, the second deceased (69-year-old) had been suffered from typhoid for the last five months, and was also obese. Of the 21 cases reported so far in the district, 20 were vaccinated except an 18-year-old.
India Gazette
3 hours ago
- India Gazette
Delhi HC grants interim bail to woman suffering from cancer
New Delhi [India], June 7 (ANI): The Delhi High Court has granted interim bail to a woman whose condition is serious due to cancer. She is an accused in a drug case registered by the Delhi Police Crime Branch under the NDPS Act. Justice Tushar Rao Gedela granted petitioner Jyoti interim bail until June 15. The High Court will hear the application on June 13. While issuing notice to the state, the bench has asked the Investigation Officer to verify the medical documents and a status report be filed within 3 days. Keeping in view the extreme and terminal medical condition of the applicant and in view of the humanitarian medical crisis which has arisen, the court allowed the application seeking interim bail. 'The applicant is enlarged on interim bail on medical grounds till.15.06.2025, subject to the applicant furnishing a personal bond of Rs . 1,00,000 with one surety of the like amount, subject to the satisfaction of the Jail Superintendent/Trial Court,' Justice Gedela ordered on June 4. Petitioner is an accused in an NDPS Act and was granted interim bail on May 19, 2025 till June 5 on the medical grounds in view of her condition. However the trial court refused to extend the interim bail as her regular bail is pending before the High court. Thereafter, an application seeking interim bail was moved before the High Court. Senior advocate Amit Chaddh,a counsel for the applicant, submitted that as per the Diagnosis Report dated 02.06.2025 of the hospital, the applicant Jyoti, aged 39 years, is suffering from Chronic Lymphocytic Leukaemia. This is an uncommon and rare kind of cancer. It was further submitted that on an application seeking further extension of the interim bail, on 04.06.2025, the Sessions Judge was not inclined to extend it further and had rejected the interim bail application holding that he had no jurisdiction, since the regular bail plea is pending before this Court. (ANI)
